2025-12-24 - Analysis Report
Okay, let's break down the analysis of RXRX (Recursion Pharmaceuticals Inc.).

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging AI to discover and develop novel therapeutics.

## 1. Return Rate Comparison

*   **RXRX Cumulative Return:** -31.02%
*   **VOO (S&P 500) Cumulative Return:** 42.87%
*   **Divergence:** -73.9 (Relative Divergence: 0.3)

**Analysis:** RXRX has significantly underperformed the S&P 500 over the tracked period. The negative divergence of -73.9 indicates a substantial difference in returns. The relative divergence of 0.3 suggests that the current divergence is near the low end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|--------|
| 2021-2023  | 22.0%  | 81.0% | 26.0% | -0.2 | 5.3    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1  | 3.6    |
| 2023-2025  | 11.0%  | 80.0% | -54.0% | 0.1  | 2.3    |

**Analysis:**
*   **CAGR:** The Compound Annual Growth Rate has declined over the periods, suggesting slowing growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and potential for large losses.
*   **Alpha:** The Alpha has turned negative and decreased significantly, indicating underperformance relative to the market.
*   **Beta:** The Beta values are relatively low, indicating that RXRX's price movements are less sensitive to overall market movements, it may be because the movements are poor.
*   **Cap(B):** Market capitalization has decreased, suggesting that the company value has shrunk.

## 2. Recent Stock Price Fluctuations

*   **Current Price:** 4.26
*   **Last-market:** Price 4.36, Previous Close 4.40, Change -0.91%
*   **5-day SMA:** 4.356
*   **20-day SMA:** 4.4978
*   **60-day SMA:** 5.0218

**Analysis:** The stock price is below all three moving averages (5-day, 20-day, and 60-day), indicating a downtrend. The current price of 4.26 and a change of -0.91% further suggest recent downward pressure.

## 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 46.19
*   **PPO:** 0.0634
*   **Hybrid Signal:** Buy 100% of cash (225 shares - Very Safe - MRI:0.90). Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -0.5 (Short-term decline)
*   **Expected Return (%):** -552.1%

**Analysis:**

*   **MRI:** The MRI of 0.8 suggests a medium level of investment risk.
*   **RSI:** The RSI of 46.19 indicates that the stock is neither overbought nor oversold.
*   **PPO:** The Positive Percentage Oscillator (PPO) of 0.0634 indicates that the 50-day moving average is slightly above the 200-day moving average.
*   **Hybrid Signal:** Suggests a strong buy signal, considering the MRI: 0.9. This signal is based on a model that considers multiple factors.
*   **Relative Divergence Change:** The negative change in relative divergence over the past 20 days confirms the recent downward trend.
*   **Expected Return:**  The extremely negative expected return (-552.1%) is a significant red flag, suggesting the model anticipates very poor performance long-term compared to the S&P 500.

## 4. Recent News & Significant Events

*   **Positive:** J.P. Morgan upgraded RXRX stock. The stock has seen gains due to the upgrade and positive trial data.
*   **Positive:** There are articles discussing RXRX as a potentially good fundamentally strong penny stock.
*   **Mixed:** News articles mention both analyst upgrades and discussions around clinical data, suggesting a mixed outlook.

**Analysis:** Recent news is generally positive, driven by analyst upgrades and encouraging trial data. However, it's important to note that these upgrades and news events may have already been factored into the recent price movement.

## 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.50, ~Hold)
*   **Opinions:** 7
*   **Target Price:** Avg: 7.00, High: 11.00, Low: 3.00
*   **Recent Rating Changes:** Not available (indicated by " → ()")

**Analysis:**  The analyst consensus is leaning towards "Buy" (bordering on "Hold"), with a significant spread in target prices. This suggests some uncertainty among analysts regarding the stock's future performance. The average target price of $7.00 indicates potential upside from the current price, but the low target of $3.00 highlights downside risks.

## 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-11-05 | -0.36 | 0.01 B$ |
| 2025-08-05 | -0.41 | 0.02 B$ |
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2025-11-05 | -0.34 | 0.03 B$ |

**Analysis:** The company is consistently reporting negative Earnings Per Share (EPS), which is concerning. Revenue is low and fluctuating. The trend in EPS appears to be slightly improving in the most recent quarters, but losses are still significant.

## 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30 | $0.00B    | -194.74%      |
| 2025-06-30 | $0.02B    | -5.54%        |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-09-30 | $1.05B     | -15.50%   |
| 2025-06-30 | $0.92B     | -18.70%   |
| 2025-03-31 | $0.93B     | -21.68%   |
| 2024-12-31 | $1.03B     | -17.29%   |
| 2024-09-30 | $0.52B     | -18.27%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent and generally low. Profit margins are predominantly negative, indicating the company is not profitable.
*   **Capital and Profitability:** Equity has fluctuated. Return on Equity (ROE) is consistently negative, confirming the company's unprofitability.

## 7. Comprehensive Analysis

**Summary:**

RXRX has significantly underperformed the S&P 500. While there has been a recent analyst upgrade and some positive news regarding trial data, the company's financials remain weak. The company exhibits high volatility, with low and fluctuating revenue and consistently negative profitability metrics (EPS, Profit Margin, ROE). The extremely negative expected return suggests caution.

**Overall Recommendation:**

Based on the provided data, a cautious approach to RXRX is warranted. While the analyst upgrade is a positive sign, the negative financial performance, high volatility, and significantly negative expected return raise concerns. A "Hold" or "Underperform" rating would be more appropriate. Investors should carefully consider their risk tolerance and conduct further due diligence before investing in RXRX.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.